Transforming Health Care - Shared Commitments for a Learning Health System [0.03%]
共建学习型卫生体系的承诺——展望医疗新时代
James L Madara,Suzanne Miyamoto,Sean C Dowdy et al.
James L Madara et al.
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial [0.03%]
月予注射玛利单抗卡法鲁肽治疗肥胖症的一项II期临床试验
Ania M Jastreboff,Donna H Ryan,Harold E Bays et al.
Ania M Jastreboff et al.
Background: Maridebart cafraglutide (known as MariTide) is a long-acting peptide-antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagoni...
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy [0.03%]
二甲双胍单药治疗控制不佳的2型糖尿病起始周剂量胰岛素依格列净治疗疗效和安全性：一项随机、双盲、安慰剂对照的III期研究
Julio Rosenstock,Timothy Bailey,Lisa Connery et al.
Julio Rosenstock et al.
Background: In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa (efsitora),...
Julie R Ingelfinger,Clifford J Rosen
Julie R Ingelfinger
The Health Equity, Medical, and Scientific Costs of Dismantling DEI [0.03%]
拆解DEI（多样性、公平和包容）对医疗保健公平性、医学及科学研究的影响及其成本
Crystal W Cené
Crystal W Cené
Madeline Conlon,Katie McBee
Madeline Conlon
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes [0.03%]
口服小分子GLP-1受体激动剂orforglipron治疗早期2型糖尿病的有效性和安全性：一项概念验证性随机临床试验
Julio Rosenstock,Stanley Hsia,Luis Nevarez Ruiz et al.
Julio Rosenstock et al.
Background: Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of or...
My Brother's Keeper [0.03%]
我兄弟的守护者
Joshua A Budhu
Joshua A Budhu
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity [0.03%]
联合使用Cagrilintide和Semaglutide治疗超重或肥胖成人患者
W Timothy Garvey,Matthias Blüher,Cynthia Karenina Osorto Contreras et al.
W Timothy Garvey et al.
Background: Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination ...
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes [0.03%]
用于超重或肥胖且患有2型糖尿病成人患者的卡格列汀-索马鲁肽疗法
Melanie J Davies,Harpreet S Bajaj,Christa Broholm et al.
Melanie J Davies et al.
Background: Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adu...